Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies
Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part of the agreement, Pathios